查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466286

伴同性诊断市场：按技术、适应症和最终用户划分 - 2024-2030 年全球预测

Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

伴同性诊断市场规模预计2023年为66.4亿美元，2024年达73亿美元，预计2030年将达到134.9亿美元，复合年增长率为10.65%。

伴同性诊断是专门的测试，旨在帮助医疗保健专业人员确定特定的医疗程序对患者是否有效，并确定该个体的最佳剂量。这些测试是个人化医疗的重要组成部分，个人化医疗是一种根据每个患者的个人特征（包括生活方式、遗传倾向和环境）提供量身定制治疗的医疗方法。伴同性诊断被广泛使用，特别是在某些癌症的治疗中，其中治疗效果可能会受到肿瘤内存在的遗传改变的极大影响。个人化医疗的发展，即根据患者个别情况优化治疗，是伴同性诊断需求的主要驱动力。此外，标靶治疗的开发，特别是在肿瘤学领域，需要伴同性诊断来识别将从这些治疗中受益最多的患者。然而，开发和引入伴同性诊断的成本高昂，报销不足是一个主要障碍。此外，次世代定序和数位 PCR 等技术正在扩展伴同性诊断的能力，并实现更全面的基因分析，为市场成长提供了巨大的机会。

主要市场统计
基准年[2023] 66.4亿美元
预测年份 [2024] 73亿美元
预测年份 [2030] 134.9亿美元
复合年增长率（%） 10.65%

科技 精准医疗领域对次世代定序仪的偏好日益增加

免疫组织化学 (IHC) 是一种透过检测组织切片中细胞中的蛋白质来诊断疾病的技术。它广泛用于癌症诊断，以识别有助于确定癌症类型及其对治疗的潜在反应的特异性标记。当诊断重点是组织样本中蛋白质表现的定位和定性评估时，首选 IHC。原位杂交 (ISH) 能够检测和定位组织切片或细胞样本中的特定 DNA 或 RNA 序列，从而深入了解基因表现和染色体畸变。该技术在检测与某些癌症相关的特定基因重排和扩增方面特别有用。次世代定序仪(NGS) 透过以前所未有的速度和规模对整个基因组或感兴趣区域进行定序，提供对基因组成的全面洞察。 NGS 是需要广泛了解遗传变异（包括小突变、拷贝数变异等）的应用的首选技术，这些变异可能与多种疾病的标靶治疗选择相关。聚合酵素链锁反应(PCR) 是一种用于增强 DNA 或 RNA 小片段以促进进一步分析的技术。 PCR 由于其简单性、敏感性和特异性而成为最广泛使用的技术之一。 PCR 因其快速处理时间而备受青睐，使其成为需要快速决策以选择治疗方法的疾病的理想选择。

最终用户製药和生物製药领域的扩展推动了伴同性诊断的重要性

製药和生物製药公司主要从事治疗药物的发现、开发和商业化。伴同性诊断的整合在标靶治疗治疗的开发过程中至关重要，特别是在癌症治疗中。这些公司需要伴同性诊断来监测治疗反应并根据需要调整治疗计划。参考文献实验室是执行复杂且先进的诊断测试的专业设施，而标准医院实验室通常无法提供这些测试。它们透过提供复杂的测试来帮助识别与特定疾病和治疗反应相关的生物标记物，在实施伴同性诊断中发挥重要作用。

区域洞察

在美洲，强大的医疗基础设施、日益​​增强的个人化医疗意识以及重要的研发活动推动了对伴同性诊断的需求。美国食品药物管理局(FDA) 在核准癌症治疗伴同性诊断方面特别积极，并强调了这些工具在治疗决策中的重要性。该地区的投资和倡议主要集中在癌症、心血管疾病和神经病学领域，反映出个人化医疗解决方案的更广泛趋势。欧盟国家对伴同性诊断表现出很高的需求，并得到强有力的法律规范促进创新，同时确保病人安全。欧洲药品管理局 (EMA) 在整个欧洲核准伴同性诊断方面发挥关键作用。欧盟消费者的需求复杂，对个人化医疗服务抱有很高的期望。在阿拉伯联合大公国和沙乌地阿拉伯等中东国家，在政府措施和医疗基础设施投资的支持下，人们对个人化医疗的兴趣与日俱增。然而，由于卫生基础设施和服务有限，非洲面临重大障碍。在亚太地区，在政府旨在普及医疗保健标准和促进个人化医疗的倡议的推动下，伴同性诊断市场正在迅速扩大。政府推出了多项推动精准医疗的倡议，包括对基因研究的大量投资。这种关注逐渐体现在对伴同性诊断不断增长的需求上，尤其是在设备齐全的都市区。

FPNV定位矩阵

FPNV 定位矩阵对于评估伴同性诊断市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对伴同性诊断市场中供应商的现状进行富有洞察力和深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.伴同性诊断市场的市场规模和预测是多少？

2.在伴同性诊断市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.伴同性诊断市场的技术趋势和法规结构是什么？

4.伴同性诊断市场主要厂商的市场占有率为何？

5.进入伴同性诊断市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 伴同性诊断在药物开发中的重要性日益增加
      • 对个人化药物和标靶治疗的需求增加
      • 加强次世代定序创新的研究与开发
    • 抑制因素
      • 开发和实施伴同性诊断的高成本
    • 机会
      • 诊断技术的持续技术进步
      • 有利的监管政策促进伴同性诊断的开发和核准
    • 任务
      • 与伴同性诊断测试相关的报销问题
  • 市场区隔分析
    • 技术：次世代定序在精准医疗中受到欢迎
    • 最终用户：製药和生物製药行业的扩张推动了伴同性诊断的重要性
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章伴同性诊断市场：依技术分类

  • 免疫组织化学
  • 原位杂交
  • 次世代定序
  • 聚合酵素链锁反应

第七章按适应症分類的伴同性诊断市场

  • 癌症
  • 心血管疾病
  • 感染疾病
  • 神经系统疾病

第八章伴同性诊断市场：依最终用户分类

  • 製药和生物製药公司
  • 参考实验室

第九章美洲伴同性诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区伴同性诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲伴同性诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Thermo Fisher Scientific 与拜耳的创新合作为精准癌症治疗树立了新标准
    • 安捷伦与 Insight 结成策略联盟，加速伴同性诊断的发展
    • 开闢新的治疗视野：FDA核准Capivasertib 和氟维司群联合治疗进行性乳癌，支持 FoundationOne® CDx 诊断的进步
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-433AB1DC2871

[194 Pages Report] The Companion Diagnostics Market size was estimated at USD 6.64 billion in 2023 and expected to reach USD 7.30 billion in 2024, at a CAGR 10.65% to reach USD 13.49 billion by 2030.

Companion diagnostics are specialized tests designed to help healthcare professionals determine whether a particular medical treatment is effective for a patient or to identify the best dosage of medication for that individual. These tests are an integral part of personalized medicine, a medical approach that tailors treatment to the individual characteristics of each patient, such as their lifestyle, genetic makeup, and environment. Companion diagnostics are particularly prevalent in the management of certain cancers, where the effectiveness of the treatment can depend significantly on the genetic alterations present within the tumor. The push towards personalized medicine, where treatments are optimized for individual patient profiles, significantly drives the demand for companion diagnostics. Moreover, the development of targeted therapies, especially in oncology, necessitates companion diagnostics to identify patients who would most benefit from these treatments. However, the development and implementation of companion diagnostics can be costly, with inadequate reimbursement posing a significant barrier. Furthermore, technologies, including next-generation sequencing and digital PCR, are expanding the capabilities of companion diagnostics, allowing for more comprehensive genetic profiling poses significant opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 6.64 billion
Estimated Year [2024] USD 7.30 billion
Forecast Year [2030] USD 13.49 billion
CAGR (%) 10.65%

Technology: Increasing preference of next-generation sequencing in precision medicine

Immunohistochemistry (IHC) is a technique used to diagnose diseases by detecting proteins in tissue section cells. It is widely employed in cancer diagnostics to identify specific markers that help in determining the type of cancer and its potential responsiveness to treatments. IHC is preferred when the diagnostic focus is on the localization and qualitative assessment of protein expressions in tissue samples. Situ Hybridization (ISH) permits the detection and localization of specific DNA or RNA sequences in tissue sections or cell samples, providing insights into gene expression and chromosomal abnormalities. This technology is particularly valuable in detecting specific gene rearrangements or amplifications associated with certain cancers. Next-generation sequencing (NGS) offers comprehensive insights into the genetic makeup by allowing the sequencing of entire genomes or targeted regions of interest at an unprecedented speed and scale. NGS is the technology of choice for applications requiring a broad understanding of genetic variations, including small mutations, copy number variations, and others that may be relevant for selecting targeted therapies across various diseases. Polymerase Chain Reaction (PCR) is a technique utilized to strengthen small segments of DNA or RNA, making it easier to conduct further analyses. It stands as one of the most widely used technologies due to its simplicity, sensitivity, and specificity. PCR is highly favored for its rapid turnaround times, making it ideal for diseases requiring quick decision-making for therapy selection.

End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics

Pharmaceutical and biopharmaceutical companies engaged primarily in the discovery, development, and commercialization of therapeutics. The integration of companion diagnostics is crucial in the drug development process, especially for targeted therapies, including those used in cancer treatment. These companies need companion diagnostics to monitor responses to therapy and adjust treatment plans as necessary. Reference laboratories are specialized facilities that perform complex and advanced diagnostic testing, often not available in standard hospital labs. They play a critical role in the implementation of companion diagnostics by providing high-complexity tests that help in the identification of biomarkers associated with specific diseases and treatment responses.

Regional Insights

In the Americas, the demand for companion diagnostics is driven by a robust healthcare infrastructure, heightened awareness about personalized medicine, and significant research and development activities. The U.S. Food and Drug Administration (FDA) has been proactive in approving companion diagnostics, especially for cancer treatments, which underscores the importance of these tools in therapeutic decisions. Investments and initiatives in this region are primarily focused on oncology, cardiovascular diseases, and neurology, reflecting a broader trend toward personalized healthcare solutions. EU countries exhibit a high demand for companion diagnostics, supported by a strong regulatory framework that promotes innovation while ensuring patient safety. The European Medicines Agency (EMA) plays an vital role in the approval of companion diagnostics across Europe. Consumer needs in the EU are sophisticated, with a high expectation for personalized healthcare services. Middle Eastern countries, such as the United Arab Emirates and Saudi Arabia, are witnessing a growing interest in personalized medicine, which is supported by government initiatives and investments in healthcare infrastructure. Africa, however, faces significant hurdles due to limited healthcare infrastructure and access. In APAC, the market for companion diagnostics is expanding swiftly, fueled by government initiatives aimed at improving healthcare standards and embracing personalized medicine. The government has launched several initiatives to promote precision medicine, including significant investments in genetic research. This focus is gradually translating into increased demand for companion diagnostics, particularly in urban areas with better healthcare facilities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Companion Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Companion Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMerieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Companion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Immunohistochemistry
    • In Situ Hybridization
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Indication
    • Cancer
      • Blood Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurological Disorders
  • End-user
    • Pharmaceutical & Biopharmaceutical Companies
    • Reference Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Companion Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Companion Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Companion Diagnostics Market?

4. What is the market share of the leading vendors in the Companion Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Companion Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing significance of companion diagnostics in drug development
      • 5.1.1.2. Increasing demand for personalized medicines and targeted therapy
      • 5.1.1.3. Rise in research and development for innovation in next generation sequencing
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with development and implementation of companion diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancements in diagnostic techniques
      • 5.1.3.2. Favorable regulatory policies encouraging the development and approval of companion diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Reimbursement issues associated with companion diagnostic tests
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Increasing preference of next-generation sequencing in precision medicine
    • 5.2.2. End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Companion Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunohistochemistry
  • 6.3. In Situ Hybridization
  • 6.4. Next-Generation Sequencing
  • 6.5. Polymerase Chain Reaction

7. Companion Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular Diseases
  • 7.4. Infectious Diseases
  • 7.5. Neurological Disorders

8. Companion Diagnostics Market, by End-user

  • 8.1. Introduction
  • 8.2. Pharmaceutical & Biopharmaceutical Companies
  • 8.3. Reference Laboratories

9. Americas Companion Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Companion Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Companion Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care
    • 12.3.2. Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development
    • 12.3.3. Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne(R) CDx Diagnostic Advances
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND COMPANION DIAGNOSTICS MA